Shows
JACC This WeekJACC Editor's Page: June 30, 2025 | JACCCardiac electrophysiology is rapidly evolving, blending procedural expertise with innovations in pharmacotherapy, device design, and lifestyle medicine. This week's Editor's Page spotlights key studies from JACC that challenge long-standing practices—from lifestyle strategies for atrial fibrillation to the role of defibrillation testing and device comparisons. We also explore disparities in cardiac arrest outcomes and complex real-world cases that push clinical boundaries. Tune in for a dynamic look at the future of arrhythmia care.2025-07-2104 minJACC This WeekIHCA Incidence Rates | JACC Deep DiveIn this JACC Deep Dive, Harlan M. Krumholz, MD, SM, FACC, discusses a new study in the July 8 issue of JACC, authored by Saket Girotra MD, SM, et al. In the study, which links national registry and Medicare data, the authors found striking hospital-level variation in cardiac arrest rates and outcomes—and identified better nurse staffing as a key factor in both preventing arrests and improving survival. Behind the scenes, the manuscript underwent multiple rounds of revision, with close collaboration between editors and authors to strengthen the analysis, add new visualizations, and clarify key takeaways. The study underscores the ne...2025-07-2106 minJACC This WeekValidation of AHA PREVENT in Healthcare Populations | JACC Deep DiveValidation of AHA PREVENT in healthcare populations| JACC Deep Dive In this JACC Deep Dive, JACC Editor in Chief Harlan M. Krumholz, MD, SM, explores a study led by Dr. Pradeep Natarajan that evaluates how well the new AHA PREVENT risk equations predict cardiovascular events across four major U.S. health systems. The study found wide variation in performance—PREVENT was well-calibrated at Penn Medicine but significantly underestimated risk at Mass General Brigham and Vanderbilt, particularly among women and minority groups. Reviewers praised the importance and rigor of the work but raised key questions about model calibration, fairness in ou...2025-07-2106 minJACC This WeekElectrophysiology in Focus: AFIB Management, LAA Closure Insights and Stroke Risk Strategies | JACC This WeekIn this episode of JACC This Week, Editor-in-Chief Harlan M. Krumholz, MD, SM, FACC spotlights major electrophysiology research and clinical insights from the July 8 issue of JACC. This week’s issue features new findings on left atrial appendage occlusion techniques, comparisons of atrial fibrillation stroke prevention guidelines across regions, and device-related complications such as pacemaker lead perforation and device embolization. You'll also hear highlights from JACC: Clinical Electrophysiology, including striking Amara Yad anatomical visuals and real-world clinical scenarios.2025-06-3007 min
JACC This WeekPodcasts at JACC: Past and Future | JACC This WeekAs the podcast series created by Editor Emeritus Valentin Fuster, MD, PhD, MACC, comes to an end and the new series from current Editor-in-Chief Harlan M. Krumholz, MD, SM, FACC is launched, JACC is pleased to feature an interview between the two legendary thought leaders, discussing the past and future of the journal's podcasts. The interview honors Dr. Fuster for his enduring contributions to the JACC podcast, highlighting his dedication, consistency, and global impact even after stepping down as Editor-in-Chief. This frank and heartfelt conversation serves as the bridge for JACC podcasts, as Dr. Fuster expresses confidence in the...2025-06-2325 min
JACC This WeekJACC Editor's Page: June 23, 2025 | JACCIn this heartfelt reflection on their first year as editor of JACC, Harlan Krumholz shares how listening—to authors, reviewers, readers, and the broader medical community—has revealed a deep yearning for connection, trust, and purpose in cardiovascular science. It’s a call to action: to shape the future of medicine with integrity, inclusivity, and hope, and to lead not just with data, but with values that inspire and unite.2025-06-2305 minJACC This WeekACS Guidelines | Closer to a Universal Document | JACCJACC’s June 10 dedicated issue on the ACS guidelines, author and former JACC Editor-in-Chief Valentin Fuster, MD, PhD, MACC, speaks with current JACC Deputy Editor Rasha Al-Lamee, MD concerning the recent ACC/AHA ACS guidelines. Dr. Fuster speaks to this comprehensive update aligning more closely with international (especially ESC) standards in acute coronary syndrome care. The interview and accompanying commentary publishing in the June 10 issue speaks to the importance of improved methodological rigor, global stakeholder inclusion, and alignment in key recommendations (e.g., DAPT duration), while also allowing greater transparency in controversial decisions and envisioning the potential for a fu...2025-06-0307 minJACC This WeekACS Guidelines | A Holistic View | JACCJACC’s June 10 issue focuses on the 2025 ACS guidelines, and this unique piece features JACC Deputy Editor James L. Januzzi Jr., Eugene Braunwald, MD, MACC, and Elliott M. Antman, MD, providing their thoughts on the historical evolution of ACS diagnosis and treatment. The discussion underscores a call to action for implementation of these comprehensive, evidence-based recommendations to improve patient outcomes. Read the article online and listen to this interview with these pioneers in the field of cardiology for additional perspectives.2025-06-0311 minJACC This WeekACS Guidelines | Gaps Within Evidence Gaps | JACCJACC Deputy Editor Lesley Curtis, PhD, speaks with authors Celina Yong, MD, FACC, and Robert M. Califf, MD, on this unique perspective piece published in JACC’s June 2 issue. Drs. Califf and Yong discuss their viewpoint article on 25 years of ACS (acute coronary syndrome) guidelines, highlighting both progress and persistent evidence gaps. While they note improvements in the proportion of recommendations based on high-quality evidence, they emphasize the fragility of this progress, the lack of applicability to diverse patient populations, and the need for broader, more inclusive research efforts to address everyday clinical questions. Integration of evidence with a fo...2025-06-0312 minJACC This WeekACS Guidelines | MCS in Acute Myocardial Infarction-Cardiogenic Shock | JACCJACC's June 10 issue, focusing on the ACS guideline, features a series of videos with unique perspectives. In this video, JACC: Executive Associate Editor Karthik Murugiah, MBBS, MHS, FACC, introduces his paper discussing the guideline's reliance on four landmark RCTs in AMI-CS. Several sweeping changes in recommendations for MCS use have been codified that should influence practice and improve care for these high-risk patients. While IABP use is expected to decrease, use of mAFP is likely to increase but should be judicious, with caution against overgeneralizing given the narrow selection criteria of DanGer Shock. Evaluating real-world practice patterns and outcomes...2025-06-0311 minJACC This WeekSORT OUT XI | EuroPCR.25 | JACCIn the latest JACC offering from EuroPCR, JACC Associate Editor Celina M. Yong, MD, FACC, interviews Dr. Ashkan Eftekhari, PhD, to discuss insights into his study, Biolimus-Eluting Biomatrix Stent Versus a Dual-Therapy Sirolimus-Eluting Stent in PCI: SORT OUT XI Randomized Trial. The biolimus A9-eluting BioMatrix Alpha stent (BES), has not been compared with another contemporary drug eluting stent. This study compared one-year target lesion failure (TLF) in BES versus the dual-therapy sirolimus-eluting Combo stent (DTS) in an all-comer population undergoing PCI. A total of 3,136 patients were randomized 1:1 to either BES or DTS. The primary result showed that BES...2025-05-2111 minJACC This WeekVutrisiran Impact on Functional Capacity and QOL | JACC Deep Dive | JACCGo behind the scenes with JACC as editor-in-chief Harlan M. Krumholz, MD, SM, FACC, talks about what 's caught his attention in the latest JACC issue on amyloid. In this paper by Sheikh et al, the authors did a pre-specified exploratory analysis from the HELIOS-B trial, evaluating vutrisiran in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The study showed that vutrisiran helped preserve or improve functional capacity and quality of life over 30 months, with consistent benefits across both monotherapy and tefamidis-treated patients. Waterfall plots illustrated the full spectrum of individual patient responses, revealing meaningful improvements in many while underscoring variability...2025-05-2008 minJACC This Week10 Year Outcome of DANAMI 3 PRIMULTI | JACC | EuroPCR.25 | JACCJACC Executive Associate Editor Karthik Murugiah, MD, FACC, speaks with author Jasmine M. Marquard, MD, PhD, on her study published in JACC and presented at EuroPCR. The discussion focuses on 10-year outcomes, including repeated events, of fractional flow reserve (FFR)-guided complete revascularization versus treatment of the infarct-related artery only in ST-segment elevation myocardial infarction. As the original trial, the primary outcome was a composite of all-cause mortality, recurrent myocardial infarction, or any revascularization. Complete revascularization reduced the risk of the primary outcome by 24%. Complete re-vascularization showed an absolute reduction of 13 events (-1 to 28 events) per 100 persons after 10 years...2025-05-1916 minJACC This WeekVutrisiran and Mortality in ATTR-CM | JACC | ESCHF25JACC: Associate Editor Michelle M. Kittleson, MD, PhD, FACC, and JACC: CardioOncology Deputy Editor Ronald Witteles, MD, FACC, discuss the current findings on the impact of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). This study on HELIOS-B comprises details on cardiovascular (CV) events and provides updated mortality analyses from a later data cut than the primary analysis. Risk of ACM and CV events, including CV hospitalizations and heart failure events, was reduced with vutrisiran versus placebo in the overall population, with consistent trends regardless of baseline tafamidis use. These findings reinforce the balanced benefit on mortality and...2025-05-1709 minJACC This WeekIndividual Variation in Tirzepatide Response | JACC Deep DiveJoin JACC Editor in Chief Harlan Krumholz, MD, SM, as he speaks about this ACC.25 presentation published in JACC. This fascinating study by Rohan Khera et al independently analyzed patient-level data from the SURMOUNT trials of tirzepatide for obesity. The study revealed striking individual variability in weight loss and metabolic response, even to a highly effective therapy—an insight powerfully illustrated through waterfall plots. Reviewers praised the transparent, sponsor-independent approach and the study’s contribution to precision medicine, though they noted it was descriptive rather than predictive, underscoring the need for future research to identify what drives differential treatment resp...2025-05-1308 minJACC This WeekJACC Editor's Page: March 18, 2025 | JACCThis special lipid-themed issue of JACC emphasizes the importance of innovative research in lipid disorders to reduce cardiovascular risk, highlighting studies that extend our understanding of lipid biology and evaluate new treatments. Key reviews and original investigations explore novel lipid-modifying therapies, such as RNA interference and antibody therapies, demonstrating their potential in managing complex lipid disorders. The issue also includes editorials and case studies that provide critical context and underscore the need for personalized and mechanism-driven approaches in lipid management.2025-05-1205 minJACC This WeekJACC Editor's Page: May 13, 2025In a time of rising global tensions, JACC reaffirms its commitment to science as a unifying, borderless force—advocating for truth, equity, and collaboration to improve health worldwide. By fostering inclusive research, promoting open dialogue, and resisting politicization, JACC aims to build a global medical community working together to overcome disease and conflict.2025-05-0507 minJACC This WeekJACC Editor's Page: May 6, 2025 | JACCListen to the editor's page for this special issue of JACC focusing on key advancements in electrophysiology, including studies on atrial fibrillation prevention, pulsed field ablation, sudden cardiac arrest in young athletes, and efforts to reduce defibrillator use in congenital heart disease. Join Editor-in-Chief Harlan Krumholz as he covers pacemaker safety, device surveillance—including insights from former FDA Commissioner Robert Califf—and emerging topics like AI monitoring and ablation mapping strategies.2025-04-2803 minJACC This WeekJACC Editor's Page: April 29, 2025 | JACCListen to the editor's page for this special issue of JACC focusing on advancing the understanding and treatment of cardiogenic shock through pivotal clinical trials, expert consensus statements, and state-of-the-art reviews aimed at improving patient outcomes. Join Editor-in-Chief Harlan Krumholz as he highlighs key contributions like the Altshock-2 trial and new ACC guidelines, the issue underscores the journal’s commitment to leading cardiovascular care in this complex field.2025-04-2103 minJACC This WeekJACC Editor's Page: April 22, 2025 | JACCListen to the editor's page of the April 14th JACC issue for a discussion about the staggering toll of cardiovascular disease on Black Americans, revealing nearly 800,000 excess deaths and 23.7 million years of potential life lost over two decades. Join Editor-in-Chief Harlan Krumholz as he explores the systemic roots of these disparities and calls for urgent, collective action to turn data into justice.2025-04-1405 minJACC This WeekJACC Editor's Page: April 15, 2025 | JACCIn a rapidly changing world marked by societal divisions, technological advances in healthcare, and shifting views on expertise, the JACC Journals remain dedicated to advancing global cardiovascular health through a science-based and humanistic approach. Committed to evidence, integrity, and humanity, JACC focuses on rigorously evaluating research, guided by facts rather than ideology, and strives to address healthcare inequities while respecting patient autonomy. As a trusted platform, it emphasizes collaboration, innovation, and inclusivity to improve cardiovascular health worldwide. By providing actionable science for clinicians and accessible insights for patients, the JACC Journals aim to lead the way in advancing cardiovascular...2025-04-0706 minJACC This WeekSmall Molecule PCSK9 Inhibitor for Hypercholesterolemia | JACC | ACC.25JACC Associate Editor Khurram Nasir, MBBS, FACC, speaks with author Michael J. Koren, MD, FACC, on his Featured Clinical Research study published in JACC and presented at ACC.25. This randomized, multicenter, double-blind, placebo-controlled, dose-ranging phase 2 study assessed efficacy, safety, and tolerability of AZD0780, a small molecule PCSK9 inhibitor. The study randomized 428 patients (426 started treatment) with hypercholesterolemia on standard-of-care statin therapy to daily oral administrations of AZD0780 1, 3, 10 or 30 mg, or matching placebo for 12 weeks. AZD0780 significantly reduced LDL-C levels versus placebo at all doses (from 35.3% to 50.7%) and demonstrated a safety and tolerability profile similar to placebo. These findings support further...2025-04-0117 minJACC This WeekIndividual Variation in Tirzepatide Response | JACC | ACC.25Join JACC Associate Editor Khurram Nasir, MBBS, FACC, and author Rohan Khera, MD, FACC, as they discuss the latest study on tirzepatide presented at ACC.25 and published in JACC. Tirzepatide, a dual GIP/GLP-1 receptor agonist, exerts pleiotropic effects on cardiometabolic health. This study evaluated its efficacy in improving cardiometabolic outcomes in individuals with T2D. An individual participant data meta-analysis was conducted, pooling data from seven Phase 3 RCTs comparing tirzepatide with placebo or standard antihyperglycemic agents. The study outcomes included cardiometabolic components of metabolic syndrome (MetS), elevated BMI, and MetS. Tirzepatide significantly reduced the odds of these abnormalities...2025-04-0117 minJACC This WeekSurvival After Sudden Cardiac Arrest in Athletes | JACC | ACC.25This discussion between JACC: Clinical Electrophysiology Associate Editor Sumeet Chugh, MD, FACC and author Jonathan Drezner discuss this research study presented at ACC.25 and published in JACC. In the observational study, they identified cases of sudden cardiac arrest (SCA) among young competitive athletes >/=11 years old from 7/1/2014-7/30/2023. During the 9-year study period, overall survival after SCA (49%,range 30-66%) and survival after exertional SCA (57%,range 38-72%) increased. Black race (RR=0.63,95% CI 0.53-0.76), Other race (RR=0.69,95% CI 0.50-0.94), and non-exertional SCA (RR=0.43,95% CI 0.32-0.59) were associated with lower survival from SCA adjusting for level of competition and sex. While survival from...2025-04-0124 minJACC This WeekSelf-Expanding Valve Outcomes at 5 Years Compared to Surgery | JACC | ACC.25Makoto Mori, MD, JACC: Associate Editor, is joined by author John K. Forrest, MD, FACC, discussing this study from Forrest et al presented at ACC.25 and published in JACC. Patients with severe aortic stenosis who were treated with either a supraannular self-expanding TAVR or surgery showed comparable rates of all-cause mortality and disabling stroke at 5 years, strengthening TAVR as a safe, effective, and durable alternative to surgery for patients, regardless of their surgical risk.2025-04-0110 min
JACC Specialty JournalsPrimary Pericardial Mesothelioma Causes Constrictive Pericarditis | JACC: Case Reports | ACC.25 | JACC: Case ReportsSandra M. Oliver-McNeil, DNP, ACNP-BC, FACC, JACC: Case Reports Associate Editor, is joined by author Victor A. Ferrari, MD, FACC discussing this study from Ravindra et al presented at ACC.25 and published in JACC: Case Reports. This clinical vignette highlights the case of a 62-year-old male who presented with worsening dyspnea and was ultimately found to have constrictive pericarditis secondary to primary pericardial mesothelioma. The use of multimodality imaging can facilitate early diagnosis of this rare condition, helping to initiate treatment options for an otherwise high-mortality disease.2025-03-2816 minJACC Specialty JournalsConservative Management of Left Atrial Dissection and Associated Complete Heart Block Following Cardiac Surgery | JACC: Case Reports | ACC.25Andrea Scotti, MD, JACC: Case Reports Deputy Editor, is joined by authors Richard Carrick, MD, PhD and Drew Bidmead, BS discussing this study from Carrick et al presented at ACC.25 and published in JACC: Case Reports. Left atrial dissection is a rare, but potentially serious, complication that most commonly arises following mitral valve surgeries. In this report, we describe an unusual case of left atrial dissection that occurred after multi-valve surgical replacement in a patient with hypertrophic cardiomyopathy. While permanent pacemaker placement was required due to recurrent episodes of complete heart block, the patient was otherwise managed safely using...2025-03-2813 minJACC Specialty JournalsMyocarditis: A Rare Cardiac Manifestation of Antiphospholipid Syndrome | JACC: Case Reports | ACC.25Mary Norine Walsh, MD, MACC, JACC: Case Reports Deputy Editor, is joined by author Alexander C Sacher, DO, discussing this study from Sacher et al presented at ACC.25 and published in JACC: Case Reports. Antiphospholipid syndrome (APS) is known for thrombotic events and pregnancy complications, but its association with myocarditis is rare and poorly understood. In this case, a 44-year-old female presented with acute chest tightness, elevated cardiac biomarkers, and severe anemia. Diagnostic workup revealed ST-segment changes on ECG, preserved left ventricular function on echocardiography, and myocardial inflammation on cardiac MRI, suggestive of acute myocarditis. Positive antiphospholipid antibodies confirmed...2025-03-2711 minJACC Specialty JournalsSymptomatic Tricuspid Valve Obstruction due to IVL | JACC: Case Reports | ACC.25Miho Fukui, MD, JACC: Case Reports Associate Editor, is joined by author Ree Lu, MD, discussing this study from Cho et al presented at ACC.25 and published in JACC: Case Reports. Intravenous leiomyomatosis (IVL) is a rare benign uterine growth that extends into the venous system. This case describes a 48-year-old female who presented with 1 month of chest pain and dyspnea on exertion. She was found to have a right atrial mass that transiently crossed into the right ventricle with associated moderate tricuspid regurgitation. Computed tomography revealed a uterine mass with contiguous intravascular extension through the inferior vena cava...2025-03-2708 minJACC Specialty JournalsTranscatheter Mechanical Aspiration of Right Ventricle Lead Vegetation | JACC: Case Reports | ACC.25Maurice Enriquez-Sarano, MD, FACC JACC: Case Reports Associate Editor, is joined by author Emmanuel Daniel, MD, discussing this study from Daniel et al presented at ACC.25 and published in JACC: Case Reports. Large lead-associated vegetations carry a significant risk of pulmonary embolism with hemodynamic instability when transvenous lead extraction is attempted. In this case, a 54-year-old male came to the hospital with fever and dyspnea. He was found to have MSSA bacteremia and a large RV lead vegetation on echo. He had multiple co-morbidities and was a high-risk surgical candidate. He underwent successful vegetation aspiration using the Flowtriever system...2025-03-2715 minJACC Specialty JournalsVitamin C Deficiency as a Reversible Cause of Pulmonary Hypertension | JACC: Case Reports | ACC.25Sandra M. Oliver-McNeil, DNP, ACNP-BC, FACC, JACC: Case Reports Deputy Editor, is joined by author Liam S. Flanagan, MD discussing this study from Flanagan et al presented at ACC.25 and published in JACC: Case Reports. Pulmonary arterial hypertension (PAH) has a diverse range of etiologies and carries significant morbidity and mortality. Here, a 45-year-old female presented with shortness of breath and was found to be in acute right heart failure due to PAH. Exam demonstrated features of scurvy. She initially required vasopressors, supplemental oxygen therapy, and PAH therapies but rapidly improved with vitamin C supplementation.2025-03-2510 minJACC Specialty JournalsMissed Kawasaki Disease Presenting as a Giant Coronary Aneurysm | JACC: Case Reports | ACC.25Julien Dreyfus, MD, PhD, JACC: Case Reports Associate Editor, is joined by author Khalid Shakfeh, MD, discussing this study from Shakfeh et al presented at ACC.25 and published in JACC: Case Reports. A 56 year old man with chronic chest pain syndrome presented with sudden onset of weakness. Evaluation for a stroke revealed a large mass in the right atrium measuring approximately 2.2 x 2.0 cm immediately above the tricuspid valve annulus and adjacent to the atrio-ventricular groove on TTE. Cardiac MRI ruled out intracardiac mass, but rather demonstrated an RCA fusiform aneurysm. Coronary CTA characterized this as two fusiform RCA aneurysms...2025-03-2508 minJACC Specialty JournalsConservative Management of Left Atrial Dissection and heart block | JACC: Case Reports | ACC.25Andrea Scotti, MD, JACC: Case Reports Deputy Editor, is joined by authors Richard Carrick, MD, PhD and Drew Bidmead, BS discussing this study from Carrick et al presented at ACC.25 and published in JACC: Case Reports. Left atrial dissection is a rare, but potentially serious, complication that most commonly arises following mitral valve surgeries. In this report, we describe an unusual case of left atrial dissection that occurred after multi-valve surgical replacement in a patient with hypertrophic cardiomyopathy. While permanent pacemaker placement was required due to recurrent episodes of complete heart block, the patient was otherwise managed safely using...2025-03-2513 minJACC Specialty JournalsCardiac Sarcoidosis Presenting as a Biatrial Mass | JACC: Case Reports | ACC.25Mary Norine Walsh, MD, MACC, JACC: Case Reports Deputy Editor, is joined by author Dena Hayes, MD, discussing this study from Hayes et al presented at ACC.25 and published in JACC: Case Reports. The diagnosis of cardiac sarcoidosis (CS) is often challenging, particularly in atypical cases. The authors describe a case of a previously healthy 33-year-old woman who was found to have a biatrial mass and evidence of a diffuse inflammatory or neoplastic process on multimodality imaging. Percutaneous biopsy of the cardiac mass was performed and histopathology revealed granulomas consistent with CS. This case adds to the growing number...2025-03-2510 minJACC This WeekUse of Cardiac Rehab in Older Patients with MI Complicated by Cardiogenic Shock | JACC | ACC.25Dhruv Kazi, MBBS, MS, FACC and first author Mohammed Essa, MD, discuss their newly published JACC Brief Report presented at ACC.25 on cardiac rehabilitation following myocardial infarction, with a focus on patients who experience cardiogenic shock. JACC: Associate Editor Jason H. Wasfy, MD, MPhil, FACC, asks questions to explore the significant underutilization of cardiac rehab, the impact of social determinants of health, and potential policy changes to improve access and outcomes. Join the conversation as they highlight key findings and the need for innovative solutions in cardiovascular care. #jacc #jaccjournals #acc252025-03-2512 minJACC This WeekEffect of plozasiran on lipoprotein particles by NMR | JACC | ACC.25In this insightful discussion, Christie Ballantyne, MD, FACC shares research on targeting APOC-III with Plozasiran to manage hypertriglyceridemia. He and JACC Associate Editor Marc P. Bonaca, MD, FACC discuss the impact on lipoprotein particle size, LDL composition, and potential cardiovascular benefits. Don’t miss this deep dive into the future of lipid management and cardiovascular risk reduction – listen now and read the study in JACC: https://www.jacc.org/doi/10.1016/j.jacc.2025.03.496 #jaccjournals #jacc #acc252025-03-2508 minJACC This WeekVutrisiran Efficacy by Baseline ATTR-CM Severity | JACC | ACC.25Watch here for a video interview with JACC Associate Editor Michelle Kittleson, MD, FACC, and author Mathew S. Muarer, MD, FACC, as they discuss Dr. Maurer’s study published in JACC and presented at ACC.25. This exploratory analysis of HELIOS-B assessed the efficacy of vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) by subgroups of baseline heart failure severity (primarily by NYHA class and NT-proBNP levels). Vutrisiran showed evidence of benefit vs placebo on mortality, cardiovascular events, functional capacity, quality of life, and cardiac biomarkers across the range of baseline disease severities in patients enrolled in HE...2025-03-2407 minJACC This WeekUse of Cardiac Rehab in Older Patients with MI Complicated by Cardiogenic Shock | JACC | ACC.25Dhruv Kazi, MBBS, MS, FACC, and first author Mohammed Essa, MD, discuss their newly published JACC Brief Report presented at ACC.25 on cardiac rehabilitation following myocardial infarction, with a focus on patients who experience cardiogenic shock. JACC: Associate Editor Jason H. Wasfy, MD, MPhil, FACC, asks questions to explore the significant underutilization of cardiac rehab, the impact of social determinants of health, and potential policy changes to improve access and outcomes. Join the conversation as they highlight key findings and the need for innovative solutions in cardiovascular care.2025-03-2412 minJACC This WeekJACC Editor's Page: March 25, 2025 | JACCListen to the editor's page of the March 25th JACC issue, in which Harlan M. Krumholz, MD, SM, FACC, highlights how cardiac electrophysiology is undergoing significant transformation driven by technological advancements and evolving treatment strategies. Key topics include long-term insights from the AMPLATZER Amulet trial, the role of intracardiac electrograms in ventricular tachycardia ablation, and shifting anticoagulation strategies in atrial fibrillation. The issue also emphasizes the growing role of device-based therapies, such as leadless pacemakers, and explores the intersection of electrophysiology with structural cardiology and precision medicine.2025-03-1709 minJACC This WeekSystolic BP & CV Mortality in US Adults Aged 80+ Taking Antihypertensive Medications| JACC | ACC.25In this video on research published in JACC and presented at ACC.25, Yuan Lu, ScD, JACC: Executive Associate Editor, discusses her study on optimal blood pressure management for adults aged 80 and above. Her study found that systolic blood pressure below 130 mmHg is associated with lower cardiovascular risk, while levels above 145 mmHg increase heart-related mortality. The study supports intensive blood pressure management but emphasizes the need for personalized treatment and further research on long-term effects and potential risks.#jacc #jaccjournals #acc252025-03-1704 minJACC This WeekCognitive Function and Patient-Reported Outcomes after Cardiogenic Shock | JACC | ACC.25In this video discussion with JACC: Associate Editor Michelle M. Kittleson, MD, PhD, FACC, and authors Eric Hall, MD and James A. de Lemos, MD, FACC, they review this study published in JACC & presented at ACC.25. Do patients who survive cardiogenic shock have neurocognitive consequences at intermediate-term follow-up? New cognitive impairment is common at discharge and 3 months after CS and is associated with worse quality of life and functional status. #jacc #jaccjournals #acc252025-03-1705 minJACC This WeekRSV and Incidence of Cardiovascular Events | JACC | ACC.25 | JACCJoin JACC: Executive Associate Editor Mitsuaki Sawano, MD, FACC, and author Mats Lassen, MD discuss Dr. Lassen’s study on the link between acute respiratory syncytial virus (RSV) infection and an increased incidence of cardiovascular events, particularly in older adults, using comprehensive nationwide data from Denmark. The findings, published in JACC and presented at ACC.25, highlight the need for heightened awareness among healthcare providers, potential adjustments in patient management during RSV season, and further research into whether RSV vaccines may help reduce cardiovascular complications. #jacc #jaccjournals #acc.252025-03-1714 minJACC This WeekJACC Editor's Page: March 18, 2025 | JACCListen to the editor's page of the March 18th JACC issue, Harlan M. Krumholz, MD, SM, and Kushal T Kadakia, MSc, examine the troubled history of the Select IVC filter, a device approved by the FDA in 2007, which was later linked to severe safety issues due to clinical trial misconduct and regulatory oversights. In this audio version of their page, they note that the case reveals systemic vulnerabilities in medical research, regulation, and publication practices, emphasizing the importance of transparency, rigorous oversight, and ethical conduct in medical device development. They propose key actions for regulators, industry, medical journals, and...2025-03-1009 min
JACC This WeekDiagnostic Performance and Clinical Impact of Photon-Counting Detector CT in CAD | JACC BaranIn this week's JACC Baran (Episode 4), hosts Mitsuaki Sawano, MD, JACC Executive Associate Editor, and Shun Kohsaka, MD, FACC, JACC Regional Editor welcome Koshiro Sakai, MD, to discuss the 2025 revised ACS guidelines and Photon-Counting CT (PCD-CT). A retrospective cohort study of 7,500 cases suggested an association between PCD-CT and enhanced diagnostic accuracy, with potential implications for reducing unnecessary invasive catheterization procedures. The episode also highlights global research perspectives and the importance of clear scientific communication.2025-03-0429 minJACC This WeekTranscatheter Aortic Valve Replacement Beyond Severe Aortic Stenosis: JACC State-of-the-Art Review | JACCIn this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.2025-03-031h 12JACC This WeekThe Evolving Landscape of TAVR: A JACC Themed Issue | JACCIn this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.2025-03-031h 12
JACC This WeekP2Y12 Inhibitor Pretreatment in Non–ST-Segment Elevation Acute Coronary Syndrome: The NCDR Chest Pain-MI Registry | JACC BaranThis episode of JACC-Baran features a brief discussion on Kendrick Lamar and the history of racial discrimination in the United States. Then Hiroki Ueyama, MD, from Emory University discusses his study on P2Y12 inhibitor pre-treatment in NST-ACS using data from the Chest Pain-MI Registry. The study examines how guideline changes have influenced clinical practice, revealing a decline in pre-treatment rates, significant practice variations, and no major differences in outcomes except for longer hospital stays in CABG patients. Watch the video or listen as a podcast here, then check out the JACC article: https://www.jacc.org/doi/10.1016/j...2025-02-2527 minJACC This WeekThe Essential Role of Cardiovascular Surgery in Cardiology - JACCJACC’s latest issue features Editor-in-Chief Harlan M. Krumholz, MD, SM, FACC, providing an audio version of his editor’s page. This collection of articles on cardiovascular surgery gives us an opportunity to reflect on the essential contributions of our surgical colleagues to the broader cardiovascular community. Read the editor’s page here: https://www.jacc.org/doi/10.1016/j.jacc.2025.01.016 and the full issue here: https://www.jacc.org/toc/jacc/85/82025-02-2407 minJACC This WeekThe Essential Role of Cardiovascular Surgery in Cardiology: A Perspective From JACC | JACCThis special issue of JACC is dedicated to the essential role of cardiovascular surgery in advancing modern cardiology.2025-02-2459 min
JACC This WeekIntroducing JACC-Baran & FINEARTS-HF Renal Function | JACC BaranIn this recording introducing the Japanese-language series of videos, JACC Executive Associate Editor Mitsuaki Sawano, MD, speaks with Shun Kohsaka, MD, FACC, and Shingo Matsumoto, MD, on topics from the effect of US government funding cuts on Japanese researchers to an in-depth discussion of the FINE-ARTS trial published in JACC, "Initial Decline in Glomerular Filtration Rate with Finerenone in HFpEF and HFmrEF: A Pre-Specified Analysis of FINEARTS-HF".2025-02-1833 min
JACC This WeekThe Super Bowl & HCM Proteomics | JACC BaranIn this second entry in the JACC-Baran Japanese language series, JACC Executive Associate Editor Mitsuaki Sawano, MD, Shun Kohsaka, MD, FACC, and Yuichi Shimada, MD, MPH, speak on topics ranging from all things Super Bowl to Dr. Shimada’s recently published JACC paper, Comprehensive Proteomic Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy.2025-02-1837 minJACC This WeekJACC - Transforming Publishing: Your Paper, Your Way at JACCHarlan Krumholz, MD, FACC, FAHA, presents the "Your Paper, Your Way" (YPYW) initiative by JACC, which streamlines the manuscript submission process to prioritize content quality over formatting requirements. By minimizing logistical barriers, providing rapid review decisions, and fostering collaboration post-acceptance, JACC aims to respect authors' time and advance high-quality science efficiently.2025-01-2806 minJACC Specialty JournalsJACC: CardioOncology Pulse - Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel RecommendationsAnne Blaes, MD, and Nicholas Wilcox, MD, MHS discuss JACC: CardioOncology Expert Panel Recommendations for cardiovascular care and surveillance after cancer therapy, including available evidence, practical recommendations, and key evidence gaps.2025-01-2822 minJACC Specialty JournalsJACC: CardioOncology - JACC: CardioOncology - January 2025 Issue SummaryDr. Ky's Introduction to Volume 7, Issue 1, of JACC: CardioOncology.2025-01-2114 minJACC This WeekJACC - Obesity as a Disease | JACCHarlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, speaks with Ania Jastreboff, MD, PhD, in this 8 part video series. In this portion, they discuss obesity as a disease.2025-01-0906 minJACC This WeekJACC - The Terminology of Obesity | JACCIn this eight part video series, JACC Editor-in-Chief Harlan M. Krumholz, MD, SM, and Ania Jastreboff, MD, PhD, discuss obesity. In this discussion, they review the language around obesity and taking care to meet patients where they are.2025-01-0902 minJACC This WeekJACC - Obesity Medication Usage | JACCHarlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, speaks with Ania Jastreboff, MD, PhD, in this 8 part video series. In this video, they discuss how cardiologists can use medications to treat obesity.2025-01-0916 minJACC This WeekJACC - Obesity Medication Concerns | JACCHarlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, speaks with Ania Jastreboff, MD, PhD, in this 8 part video series. In this portion, they discuss concerns around the range of popular obesity medications today.2025-01-0901 minJACC This WeekJACC - Shame and Blame | JACCHarlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, speaks with Ania Jastreboff, MD, PhD, in this 8 part video series. In this portion, they discuss patients with obesity and society's view of obesity, as well as the role of the CV physician in shifting the culture around obesity.2025-01-0907 minJACC This WeekJACC - Is There Healthy Obesity? | JACCHarlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, speaks with Ania Jastreboff, MD, PhD, in this 8 part video series. In this portion, they discuss if patients can be healthy and have obesity, as well as the many impacts that obesity can have on patients.2025-01-0906 minJACC This WeekJACC - The Cardiologist's Role in Treating Obesity | JACCHarlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, speaks with Ania Jastreboff, MD, PhD, in this 8 part video series. In this portion, they discuss how and why cardiovascular physicians can and should learn about the medications to treat patients with obesity.2025-01-0907 minJACC This WeekJACC - Should Cardiologists Care About Obesity? | JACCHarlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, speaks with Ania Jastreboff, MD, PhD, in this 8 part video series. In this portion, they discuss why cardiologists should care about obesity, and how JACC is raising awareness of treating obesity and helping patients.2025-01-0903 minJACC Specialty JournalsJACC - The Cardiologist's Role in Treating Obesity | JACCHarlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, speaks with Ania Jastreboff, MD, PhD, in this 8 part video series. In this portion, they discuss how and why cardiovascular physicians can and should learn about the medications to treat patients with obesity.2025-01-0807 min
Heart Corner: Innovations in Cardiovascular ScienceEpisode #19: Triple Take: 3 Manuscripts from JACC1. Généreux, P, Banovic, M, Kang, D. et al. Aortic Valve Replacement vs Clinical Surveillance in Asymptomatic Severe Aortic Stenosis: A Systematic Review and Meta-Analysis. JACC. null2024, 0 (0) . https://doi.org/10.1016/j.jacc.2024.11.006
2. Warraich, H, Patrick-Lake, B, Saha, A. et al. Digital Health Technologies for Cardiometabolic Disease and Diabetes: A Perspective From the U.S. Food and Drug Administration. JACC. null2024, 0 (0) .
https://doi.org/10.1016/j.jacc.2024.10.075
3. Jain, S, Sarraju, A, Shah, N. et al. The Coming AI Revolution in Clinical Trials. JACC. null2024, 0 (0) .https://doi.org/10.1016/j.jacc.2024.10.0932024-12-0712 minJACC Specialty JournalsJACC: Case Reports - TEER for SAM of the Mitral Valve and Flail Posterior Mitral Leaflet: One Clip SolutionJACC: Case Reports Associate Editor Maurizio Taramasso, MD, PhD, joins author Brinder S Kanda, MD, FACC to discuss their case presented at AHA and published in JACC: Case Reports. In this case, an 83-year-old female with decompensated heart failure was found to have HOCM with SAM of the mitral valve and a large P2 flail segment with ruptured cords. TEER was performed resulting in mild MR and resolution of the prior LVOT gradient. The case supports TEER for patients with medication-refractory HOCM.2024-12-0209 minJACC This WeekJACC - Recap of AHA From Harlan Krumholz, Editor-in-ChiefHarlan Krumholz, editor-in-chief of JACC, provides a wrap-up of the JACC papers at the AHA Scientific Sessions in Chicago in 2024. JACC's Obesity Revolution page features various trials to provide perspectives on obesity, including SUMMIT, LookAHEAD, and SELECT. Other studies featured include the DANGER trial; REALIZE-K; AMPLATZER; HELIOS-B; a study on sedentary behaviors from the UK Biobank; systolic pressure and blood pressure in patients with HFpEF; rural and urban differences in cardiovascular mortality from 2010-2022; and the association of hospital cardiologist integration with patient outcomes2024-11-2014 minJACC This WeekJACC - Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart FailureJACC Associate Editor Michelle M. Kittleson, MD, PhD, FACC, interviews author Mikhail Kosiborod, MD, FACC about his REALIZE-K study published in JACC and presented at AHA. In participants with HFrEF and hyperkalemia, SZC led to large improvements in the percentage of participants with normokalemia while on optimal spironolactone dose, and reduced risk of hyperkalemia and down-titration/discontinuation of spironolactone. More participants had HF events with SZC than placebo; this difference was limited to those with very high NTproBNP levels.2024-11-2018 minJACC This WeekJACC - Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and ObesityJACC Associate Editor Marc P. Bonaca, MD, FACC, speaks with author Subodh Verma, MD, PhD, and A. Michael A. Lincoff, MD, FACC, about this brief report published in JACC and presented at AHA. Following CABG surgery there remains a markedly high risk of persistent ischemic events, heart failure, and mortality. Semaglutide consistently reduced all cardiovascular outcomes in this population.2024-11-2017 minJACC This WeekJACC - Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR SubstudyJACC Associate Editor Neha J. Pagidipati, MD, FACC, speaks with author Christopher M. Kramer, MD, FACC about this substudy of the SUMMIT trial published in JACC and presented at AHA, demonstrating that tirzepatide therapy in obesity-related HFpEF led to reduced LV mass and paracardiac adipose tissue as compared to placebo and the change in LV mass paralleled weight loss. These physiologic changes may contribute to the reduction in heart failure events seen in the main SUMMIT trial.2024-11-2014 minJACC This WeekJACC - Outpatient Worsening Heart Failure in Patients with ATTR CM in the HELIOS-B Trial | JACC | AHA 2024JACC: Associate Editor Michelle M. Kittleson, MD, PhD, FACC, talks with authors Scott Solomon, MD, FACC and. Marianna Fontana, MD, about their study published in JACC and presented at AHA. Outpatient worsening heart failure (HF) (oral diuretic intensification or initiation) is simple to assess and has been shown to be prognostic of mortality in patients with ATTR-CM. In this pre-specified analysis of a contemporary ATTR-CM population, patients with outpatient worsening HF had an increased risk of all-cause mortality and CV events and all-cause mortality, as well as greater deterioration in assessments of functional capacity, health status, and quality of...2024-11-2010 minJACC This WeekJACC - Intensive lifestyle intervention, cardiac biomarkers, and cardiovascular outcomes in diabetes: LookAHEAD cardiac biomarker ancillary studyJACC Associate Editor Muthiah Vaduganathan, MD speaks with author Ambarish Pandey, MD about the LookAHEAD trial published in JACC and presented at AHA. Among adults with T2D and overweight/obesity in the Look Action for Health in Diabetes (AHEAD) trial, an intensive lifestyle intervention targeting weight loss led to sustained reductions in hs-cTnT at 1- and 4-year follow-up, and a rise in NT-proBNP at 1 year that attenuated at 4 years. After accounting for baseline biomarker levels and baseline and changes in risk factors, longitudinal increase in NT-proBNP was associated with higher risk of ASCVD and incident HF. In contrast...2024-11-2006 minJACC This WeekJACC - DanGer Shock trial: The impact of age | JACC | AHA 2024JACC: Associate Editor Celina Yong, MD, interviews author Jacob Eifer Møller, PhD about his DANGER SHOCK paper presented at AHA and published in JACC. The DanGer Shock trial demonstrated reduced mortality in patients with STEMI-related cardiogenic shock treated with a microaxial flow pump (mAFP). This secondary analysis assessed whether age affected survival benefits. Mortality increased incrementally with age, and age was independently associated with outcome. Spline analysis suggested that the risk of mortality was higher in the standard-care group for patients below 77 years, whereas patients aged 77 or older had a higher predicted risk in the mAFP group. Thus, e...2024-11-2014 minJACC This WeekJACC - Oxidized Phospholipids and Calcific Aortic Valvular DiseaseJACC Associate Editor Marc P. Bonaca, MD, FACC, has a discussion with author Sotirios Tsimikas, MD, FACC about this study on phospholipids presented at AHA and published in JACC. In MESA, both OxPL-apoB and Lp(a) were independently associated with prevalent AVC with a significant interaction between the two (p less than 0.01). OxPL-apoB and Lp(a) were associated with incident AVC at 9.5 years when evaluated independently (interaction p less than 0.01). The OxPL-apoB*Lp(a) interaction demonstrated higher odds of prevalent and incident AVC for OxPL-apoB with increasing Lp(a) levels. In the meta-analysis, both OxPL-apoB and Lp(a) were...2024-11-2016 minJACC This WeekJACC - Accelerometer-Measured Sedentary Behavior & Risk of Future Cardiovascular Disease | JACC | AHA 2024JACC Associate Editor Xiaoxi Yao, MPH, MS, PhD, FACC, interviews author Shaan Khurshid, MD and Ezimamaka Ajufo, MD, about their study on sedentary behavior presented at AHA and published in JACC. Beyond serving as a marker for insufficient physical activity, sedentary behavior may directly affect risk of future cardiovascular (CV) disease. In 89,530 UK biobank participants, greater accelerometer-measured sedentary time was associated with higher incidence of adverse CV events. Associations with sedentary time were particularly robust for HF and CV mortality, where risk inflected at approximately 10.6 hours/day and remained apparent even among individuals meeting guideline-recommended levels of moderate-to-vigorous physical...2024-11-2008 minJACC This WeekJACC - P2Y12 Inhibitor Pretreatment in Non-ST Elevation Acute Coronary Syndrome: The NCDR Chest Pain-MI RegistryJACC Associate Editor Seng Chan You, MD, and author Hiroki Ueyama, MD discuss this study presented at AHA and published in JACC. NCDR study finds a steady decline in P2Y12 inhibitor pretreatment for NSTE-ACS in the US, but significant variability persists among operators, institutions, and regions. This practice was not associated with any benefits but was linked to a longer length of stay among those undergoing CABG, underscoring the importance of maintaining efforts to integrate evidence into clinical practice.2024-11-2015 minJACC This WeekJACC - Hospital-Cardiologist Integration and Outcomes | JACC | AHA 2024JACC Associate Editor Jason H. Wasfy, MD, MPhil, FACC interviews author Vinay Kini, MD, FACC about this hospital integration study published in JACC and presented at AHA. Cardiologist employment by hospitals is increasing, but the impact on care quality is not well understood. The study identified cardiologists who cared for acute myocardial infarction or heart failure patients between 2008-2019. Outcomes were compared for patients treated by cardiologists who switched to hospital employment versus cardiologists who remained independent. The proportion of hospital-employed cardiologists increased from 26% in 2008 to 63% in 2019. The study found no differences in clinical outcomes (e.g., 30-day mortality...2024-11-2016 minJACC Specialty JournalsJACC: Case Reports - TEER for SAM of the Mitral Valve and Flail Posterior Mitral Leaflet: One Clip SolutionJACC: Case Reports Associate Editor Maurizio Taramasso, MD, PhD, joins author Brinder S Kanda, MD, FACC to discuss their case presented at AHA and published in JACC: Case Reports. In this case, an 83-year-old female with decompensated heart failure was found to have HOCM with SAM of the mitral valve and a large P2 flail segment with ruptured cords. TEER was performed resulting in mild MR and resolution of the prior LVOT gradient. The case supports TEER for patients with medication-refractory HOCM.2024-11-2009 minJACC This WeekJACC Journals at AHA | JACC | AHA 2024Join Harlan Krumholz, editor-in-chief of JACC, as he highlights groundbreaking cardiovascular science presented at this year's American Heart Association Scientific Sessions. From obesity-related heart failure to innovations in stroke prevention and disparities in care, this episode delves into pivotal studies shaping the future of cardiology and their real-world clinical implications.2024-11-1303 minJACC This WeekJACC - November 5, 2024 Issue SummaryIn the November 5, 2024 issue of JACC, Dr. Valentin Fuster summarizes the November 5, 2024 issue of the JACC, which focuses exclusively on hypertrophic cardiomyopathy (HCM). Highlighting six original research papers, the discussion emphasizes the groundbreaking impact of the cardiac myosin inhibitor Aficamten on health outcomes, symptom burden, and cardiac structure in patients with obstructive HCM, while also exploring genetic screening implications for affected families.2024-10-2823 min
Sakura Radio日本芸術文化センター（JACC）創設者代表・武道家 大美明広先生：EP132 全米情報番組「HELLO AMERICA」HELLO AMERICA 毎週水曜日午前10時15分〜（EST)ほか 全米の話題をローカル情報も交えながらお届け。 ニュース、ローカルリポート、アメリカで活動する日本人へのインタビュー、各地のイベント情報などなど、週替わりのキャスターがそれぞれの地域から放送。 2024年10月16日放送：今週は福野理恵がお届けします。文化とスポーツの秋ですね。
シリコンバレーのミツワのモールの奥には 畳の武道場がありましてアメリカにいながら様々な日本の文化が学べるようになっています。今回はその武道場兼文化センター、日本芸術文化センター（通称JACC）の創設者代表で武道家の大美明広（おおみあきひろ）先生にお話を伺います。
大美先生はシリコンバレーのIT企業で働きながらも全米空手道連盟の役員や世界審判員として、空手のオリンピック参加に奔走されたり空手の全米シニア大会（型の部）でチャンピオンになられたこともある方です。
そんな大美先生のアメリカへ来たきっかけや苦労、武道や瞑想で発達障害を克服する子どもたちの話世界のマーシャルアートと武道との大きな違い今後JACCを通して描いているビジョンなどについて伺いました。お楽しみに！
日本芸術文化センター（JACC）のHP: http://www.jpnarts.org/
ドネーションはこちらから: http://www.jpnarts.org/donate.html
☆また、『Local Information』 では秋らしい様々なイベントをご紹介！
オレンジカウンティで行われるNVF運動会https://novavitafoundation.org/nvf-events/nvf-undokai/
ヒューストンの「和酒フェス」 https://sakefoodfest.com/
シリコンバレーで開催される「ウィコラDay2024」https://www.wecolla.org/events-classes/special-events2024-10-1736 minJACC This WeekPart Two: Time to Significant Benefit of Finerenone in Patients With Heart Failure | JACC | HFSA 2024Michelle M Kittleson, MD, FACC, JACC Associate Editor, speaks with author Muthiah Vaduganathan, MD on his accepted paper concerning the FINEARTS trial published in JACC.2024-10-0411 minJACC This WeekFinerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial | JACC | HFSA 2024Akshay S. Desai, MD, FACC presents his accepted HFSA presentation concerning the FINEARTS trial published in JACC, with commentary by Theresa McDonagh, MBBCH, JACC Associate Editor.2024-10-0418 min
Knox Brew StoriesKnox Brew Stories: 06/03/24 (Jacc Moran & Bill Foster)Knox Brew Stories is a weekly live radio show and podcast that offers an in-depth look at the craft beer scene in Knoxville, and the latest craft beer news from around the country and all over the world.Support us on Patreon! Head to https://www.patreon.com/knoxbrewstories to check out the different ways you can show your support while receiving exclusive content, a shoutout on-air, and backstage passes to members-only events and merch!In this episode you’ll find our regular weekly news about craft beer, as well as:...2024-06-0400 min
Star Update Podcast - Cardiology News SummariesManagement of Severe Mitral Regurgitation in Patients With Acute Myocardial Infarction: JACC Focus Seminar 2/5Management of Severe Mitral Regurgitation in Patients With Acute Myocardial Infarction: JACC Focus Seminar 2/5
J Am Coll Cardiol . 2024 May 7;83(18):1799-1817. doi:
10.1016/j.jacc.2023.09.840
Abstract
Severe acute mitral regurgitation after myocardial
infarction includes partial and complete papillary muscle rupture or functional mitral regurgitation. Although its incidence is 2024-05-3101 min
Parallax by Ankur KalraEP 107: JACC: Advances - Leadership & the Future of Publishing with Dr SilversidesJoin Dr Ankur Kalra on Parallax this week as he welcomes Dr Candice K Silversides, the first Editor-in-Chief of JACC: Advances.
Dr Silversides, a cardiologist and professor at the University of Toronto, wears many hats. She leads the Obstetric Medicine program and directs the Cardio-Obstetric clinic at Mount Sinai Hospital, while simultaneously steering JACC: Advances in its exciting early stages.
Dive into the unique synergy between her clinical practice and editorial leadership as Dr Silversides shares her vision for the journal. Learn how she navigates diverse responsibilities, manages peer reviews, and ensures fair evaluation of the submitted manuscripts. Get insights...2024-02-1243 minJACC Specialty JournalsJACC: CardioOncology Pulse - ESC 2023 JACC: CardioOncology Sim Pub: Chest Pain in Cancer Patients: Prevalence of Myocardial Infarction and Performance of High-Sensitivity Cardiac TroponinsPaolo Bima, MD and Professor Christian E. Mueller MD, FESC discuss key takeaways from their study on prevalence of myocardial infarction in cancer patients and review the clinical implications of their findings. Moderated by JACC: CardioOncology Editor-in-Chief Bonnie Ky, MD, MSCE, FACC.2023-09-0518 min
OVERSHARING hosted by Mikhail AlfonIncremental Changes Toward Fulfillment with Jacc SanchezJacc Sanchez is the co-founder and Director of Operations at Moxi3 Fitness in Costa Mesa, CA. Connect with Jacc on Instagram Visit Moxi3 Fitness Connect with Mikhail on Instagram2022-04-0455 min
OVERSHARING hosted by Mikhail AlfonMaking Incremental Changes Toward Fulfillment with Jacc SanchezJacc Sanchez is the co-founder and Director of Operations at Moxi3 Fitness in Costa Mesa, CA. Connect with Jacc on Instagram Visit Moxi3 Fitness Connect with Mikhail on Instagram2022-04-0455 minOVERSHARING hosted by Mikhail AlfonMaking Incremental Changes Toward Fulfillment with Jacc SanchezJacc Sanchez is the co-founder and Director of Operations at Moxi3 Fitness in Costa Mesa, CA. Connect with Jacc on Instagram Visit Moxi3 Fitness Connect with Mikhail on Instagram2022-04-0255 min
Manifest JaccUntrueWritten, Produced, & Mixed By: NuthinbutAce(Manifest Jacc)
Follow @ManifestJacc2022-02-2101 min
Cardio EdOmecamtiv mecarbil & GALACTIC-HF trial (NEJM 2021& JACC 2021)Role of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF) was published in GALACTIC- HF trial (NEJM 2021). Recently, in JACC the effect of ejection fraction on response to Omecamtiv mecarbil in patients enrolled in GALACTIC-HF trial was published.
In this presentation I have discussed both these studies together.
Omecamtiv mecarbil may find its place in newer guidelines for HFrEF.
To know more about Omecamtiv mecarbil in patients with HFrEF and both the trials published in NEJM and JACC listen to this podcast.2021-07-1708 min
"jUSt SLaP Yo SELf" ShOWGØdZ!LLa gÖDz1LLARandom First Time Heard BeatZ captured MoMeNt§ in the World of JaCC FrOsT... DaRE You NOT to LiSTEN..2021-06-1411 min
"jUSt SLaP Yo SELf" ShOWSimpLe MAN/WaLk OnDArE YoU to Li§t3N.... hahaha FrEeStyLe AdVenTUre§ into the NiGhtZ. FIRST time Heard Random Beatz/!nstrUmentaLz. Da AdAptAt!Øn!§t MoNsTAz 1nC JaCc FrO$t aka $shhhhh. Hahaha EnJOY2021-05-1607 min
Fire In Little Africa PodcastEpisode 52: Jacc SpadeJacc Spade is a producer, mixing engineer and entrepreneur from North Tulsa. Known as one of the most respected engineers in the game and an all around legend in Tulsa, Jacc Spade has been running his own studio since the earliest days of the Tulsa hip-hop scene. He has mixed countless classic Tulsa hip-hop records, most recently Dr. View’s (In) Visible Man, Dredastacca - Voice of the Trap 2, and of course Fire in Little Africa.In this episode, Ali and Doc catch up with Jacc Spade on Zoom for a deep dive into the Fire In Li...2021-03-301h 15
RWBY RPGRWBY Team JACC E:5 Combat Lesson!MY NAME IS TANNIM WOODALL AND I WILL BE YOUR GM FOR THIS CAMPAIGN! WELCOME TO EPISODE 5 OF RWBY TEAM JACC! HERE WE CONTINUE THE ADVENTURE OF TEAM JACC. NOW STARTING THERE FIRST DAY OF CLASSES! GETTING A "HANDS ON" LESSON ON THE MIGHT OF A TRUE HUNTSMAN!!
JAE MERAL: ADDEN TRUESDALE
AZURE ALI: BRADY ROWE
COLBY HEART: MATTHEW WEST
CHARLOTTE CHATON: BETH MYERS
HOPEFULLY YOU GUYS ENJOY, AND IF YOU DO SHOW US YOUR SUPPORT BY GOING TO
FACEBOOK www.facebook.com/teamjacc
2018-12-261h 13RWBY RPGRWBY Team JACC E:4 Team JACC!!MY NAME IS TANNIM WOODALL AND I WILL BE YOUR GM FOR THIS CAMPAIGN! WELCOME TO EPISODE 4 OF RWBY TEAM JACC! HERE WE CONTINUE THE ADVENTURE OF TEAM JACC. NOW ALL TOGETHER AT THE CORE OF "SIRRIUS LABRINTH" HERE THEY WILL FACE MASSIVE OBSTICLES IN THERE PATH... BUT LUCKILY THEY WONT BE ALONE.......
JAE MERAL: ADDEN TRUESDALE
AZURE ALI: BRADY ROWE
COLBY HEART: MATTHEW WEST
CHARLOTTE CHATON: BETH MYERS
HOPEFULLY YOU GUYS ENJOY, AND IF YOU DO SHOW US YOUR SUPPORT BY GOING TO
FACEBOOK www.facebook.com/teamjacc
OR INSTAGRAM @rwbyteamjacc
AND GIVE US A FOLLOW OR LIKE! ALSO...2018-10-2937 minRWBY RPGRWBY Team JACC E:3 Lets Get Sirrius!MY NAME IS TANNIM WOODALL AND I WILL BE YOUR GM FOR THIS CAMPAIGN! WELCOME TO EPISODE 3 OF RWBY TEAM JACC! HERE WE CONTINUE THE ADVENTURE OF TEAM JACC. SOON TO ENTER THE TREACHEROUS "SIRRIUS LABRINTH"! LETS JUST HOPE THEY CAN HANDLE IT!
JAE MERAL: ADDEN TRUESDALE
AZURE ALI: BRADY ROWE
COLBY HEART: MATTHEW WEST
CHARLOTTE CHATON: BETH MYERS
HOPEFULLY YOU GUYS ENJOY, AND IF YOU DO SHOW US YOUR SUPPORT BY GOING TO
FACEBOOK www.facebook.com/teamjacc
OR INSTAGRAM @rwbyteamjacc
AND GIVE US A FOLLOW OR LIKE! ALSO IF ANY OF YOU HAVE AN OC THAT YOU WOULD...2018-10-2550 minRWBY RPGRWBY Team JACC E:2 WELCOME TO HAVENMY NAME IS TANNIM WOODALL AND I WILL BE YOUR GM FOR THIS CAMPAIGN! WELCOME TO EPISODE 2 OF RWBY TEAM JACC! HERE WE CONTINUE THE ADVENTURE OF TEAM JACC. GETTING TO MEET SOME... INTERESTING CHARACTERS..
JAE MERAL: ADDEN TRUESDALE
AZURE ALI: BRADY ROWE
COLBY HEART: MATTHEW WEST
CHARLOTTE CHATON: BETH MYERS
HOPEFULLY YOU GUYS ENJOY, AND IF YOU DO SHOW US YOUR SUPPORT BY GOING TO
FACEBOOK www.facebook.com/teamjacc
OR INSTAGRAM @rwbyteamjacc
AND GIVE US A FOLLOW OR LIKE! ALSO IF ANY OF YOU HAVE AN OC THAT YOU WOULD LIKE TO SEE HAVE BECOME AN NPC ON...2018-09-1629 minRWBY RPGRWBY Team JACC E: 1 A NEW TALEHELLO EVERYONE!
MY NAME IS TANNIM WOODALL AND I WILL BE YOUR GM FOR THIS CAMPAIGN! WELCOME TO THE FIRST EPISODE OF RWBY TEAM JACC! HERE WE WILL BE INTRODUCED TO THE MEMBERS OF TEAM JACC.
JAE MERAL: ADDEN TRUESDALE
AZURE ALI: BRADY ROWE
COLBY HEART: MATTHEW WEST
CHARLOTTE CHATON: BETH MYERS
HOPEFULLY YOU GUYS ENJOY, AND IF YOU DO SHOW US YOUR SUPPORT BY GOING TO
FACEBOOK www.facebook.com/teamjacc
OR INSTAGRAM @rwbyteamjacc
AND GIVE US A FOLLOW OR LIKE! ALSO IF ANY OF YOU HAVE AN OC THAT YOU WOULD LIKE TO SEE HAVE BECOME AN NPC...2018-09-0851 min
JaCc FrOSt'S ShOwAssHoLeFrEEStYLiN to FiRsT TiMe HeArD RAnDoM inSTruMeNtaL BeATzz about Being the ASSHoLE... Be it Female Or Male JaCc FrØ$t dOnt PLaY GaM3z so No Need to Explain but M3×My§3Lf=iv2018-08-2603 min